Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
- Conditions
- Interventions
- First Posted Date
- 2003-04-24
- Last Posted Date
- 2009-08-07
- Target Recruit Count
- 16
- Registration Number
- NCT00059358
- Locations
- 🇵🇷
UPR Adult ACTU, San Juan, Puerto Rico
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
- First Posted Date
- 2003-03-25
- Last Posted Date
- 2013-12-06
- Target Recruit Count
- 58
- Registration Number
- NCT00056862
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Treatment of Hepatitis C in Hemophilic Patients With HIV
- Conditions
- First Posted Date
- 2003-02-27
- Last Posted Date
- 2008-07-30
- Target Recruit Count
- 22
- Registration Number
- NCT00055341
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00016081
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
- Conditions
Hepatitis C Antiviral Resistance in African-Americans
- First Posted Date
- 2002-06-10
- Last Posted Date
- 2017-08-03
- Target Recruit Count
- 401
- Registration Number
- NCT00038974
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 15
- Registration Number
- NCT00000772
- Locations
- 🇺🇸
Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
🇺🇸University of Minnesota, ACTU, Minneapolis, Minnesota, United States
A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 96
- Registration Number
- NCT00001015
- Locations
- 🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
🇺🇸Univ of California / San Diego Treatment Ctr, San Diego, California, United States
The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- ICN Pharmaceuticals
- Registration Number
- NCT00002298
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 130
- Registration Number
- NCT00001123
- Locations
- 🇺🇸
NIAID/DMID/CASG Central Unit, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.